Risedronate Sodium Tablet, Film Coated
Product Images NDC 33342-107

This text contains information about Risedronate Sodium Tablets, which are used once-a-day. The medication guide should be provided to patients. The tablets are available in a batch of 30 tablets (3x10 unit-dose tablets). Risedronate Sodium Tablets are manufactured by Macleods Pharmaceuticals Lt. in India and distributed by Macleods Pharma USA, Inc. They should be stored in a controlled room temperature of 15°C to 30°C. The usual dosage should be followed as directed in the Prescribing Information. This information is useful for anyone seeking to learn about Risedronate Sodium Tablets.*

This is a medication package for Risedronate Sodium Tablets, USP, with NDC number 33342-108-15 manufactured by Macleods Pharma USA, Inc. Each film-coated tablet contains Risedronate Sodium, USP 30 mg, and is meant for once-a-day usage. The usual dosage can be found in the prescribing information for dosage and administration. The medication guide included in the package should be provided to each patient by the pharmacist. The tablets should be stored at a temperature of 20° to 25°C (68° to 77°F), and should not be accessible to children.*

Each film-coated tablet contains Risedronate Sodium, USP 30 mg. It is typically taken once a day as per the prescribing information provided for dosage and administration. Store the tablets at 20° to 25°C (68° to 77°F) with excursions allowed at 15°C to 30°C (59° to 86°F), but keep them away from children. This medication is manufactured for and by Madleods Pharmaceuticals Ltd. The code number is HPI152/07, and each packet contains 30 tablets.*

Each tablet contains 5mg of Risedronate Sodium, USP. It is indicated in the prescribing information for Dosage and Administration. The tablets should be stored at a temperature of 20° to 25°C (68° to 77°F) with excursions permitted to 15°C to 30°C. Macleods Pharma USA, Inc. has manufactured it for Macleods Pharmaceuticals Ltd. Keep out of reach of children. It comes with medication guidance for patients.*

Pharma USA is a medication that contains Risedronate Sodium Tablets (5mg). A batch number, expiration date, and manufacturing information are also provided on the label. The pharmacist is directed to distribute a medication guide to each patient. The recommended storage temperature is between 20-25°C, with controlled room temperature recommended. The usual dosage is specified in the prescribing information. The label advises keeping the medication out of reach of children.*

This is a description of a medication called "Baczoos" which contains Risedronate Sodium (5mg) in a coated tablet form. The recommended dosage information can be found in the prescribing information. The tablets should be stored in controlled room temperature and out of reach of children. The medication is manufactured by Macleods Pharmaceuticals Ltd. It comes in a package of 30 tablets and has a code no of HP/152/07, and PM02005403.*

Once-a-Week risedronate sodium tablets, USP is a medication supplied in a blister pack with instructions for opening blister pack. The tablets should be taken orally with plain water once a week, and patients should not consume food, drinks, or other medication for 30 minutes after taking the tablet. The usual dosage should be verified via Prescribing Information, and pharmacists should provide a Medication Guide to each patient. This product is manufactured by Macleods Pharmaceuticals Ltd., India, and distributed by Macleods Pharma USA, Inc. in Princeton, NJ. There is no information available regarding the text fragment "& dsn'sisjgel WNIpog 8jeuoIpasy," as it is not legible.*

The text provides instructions for opening a blister pack containing a 4 week supply of Risedronate Sodium Tablets, USP, which should be taken once a week on the same day. It includes the manufacturer's name and location, dosage directions, and storage temperature requirements. There is also a reminder to dispense the accompanying medication guide to each patient.*

The text is describing a figure showing the change in bone mineral density (BMD) from baseline for patients who have recently initiated glucocorticoid therapy. The figure shows different treatments including placebo, risedronate sodium 5mg, and others, with varying numbers of patients represented in each treatment group. The change in BMD is shown for the lumbar spine, femoral neck, and trochanter.*

This is a chart showing the change in bone mineral density (BMD) for patients on long-term Glucocorticoid Therapy, comparing the effects of Placebo and Risedronate Sodium 5mg. The BMD results are displayed for three different parts of the body - Lumbar Spine, Femoral Neck, and Trochanter. The sample size for each group is also shown.*

This is a graph showing the incidence of vertebral fractures in patients who are starting or continuing glucocorticoid therapy. The graph displays the placebo group and the group taking Risedronate Sodium 5 mg. The number of patients and incidence percentage is also shown for each group.*

This appears to be a graph with different treatments and showing the mean percentage change from baseline in serum alkaline phosphatase excess by visit. The treatments are DIDRONEL 400 mg and Risedronate Sodium 30 mg. The graph has different visit days with corresponding percentages displayed on the y-axis.*